FDA Panel Supports Ketek as Second-Line for CAP; Suggests Black Box

Sanofi-Aventis' Ketek should not be the first-line treatment for community acquired pneumonia, members of an FDA advisory panel cautioned when they recommended continued marketing of the antibiotic for CAP